NeurogesX
San Carlos, California, United States
About NeurogesX
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $135.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2012)
- Ticker: otcbb:NGSX
- Website: neurogesx.com
- Phone: 16503198757
Industries & Categories
Biotechnology, Medical, Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/neurogesx-2517937 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.